Introduction
The genetic basis of the Mendelian cardiac rhythm disorders associated with sudden cardiac death (SCD) has been brought into focus over the last 20 years with the discovery of a large spectrum of causal mutations in genes encoding components of cardiac ion channels. 1 Although this enabled genetic testing and consequently improvements in clinical care, patient management is still hindered by the reduced penetrance and substantial variability in disease severity and SCD risk among mutation-positive individuals. 1 Although co-morbidities are expected to modulate disease severity, these remain unexplored.
Identification of disease modifiers in these disorders is however hindered by the substantial genetic heterogeneity across patients, as different mutations may be associated with different effects and thus also contribute to inter-individual variability. 2 Studies in large families that harbour founder mutations (where all affected individuals carry the same familial mutation) circumvent this limitation and therefore offer opportunities for the identification of modulatory factors.
We have previously described a large Dutch family harbouring a founder mutation, p.Tyr1795_Glu1796insAsp (previously called 'SCN5A-1795insD'), in the SCN5A gene, which encodes the major sodium channel isoform in heart (Na V 1.5) . 3, 4 This mutation displays multiple biophysical defects and causes 'overlap' sodium channelopathy with features of long QT syndrome, Brugada syndrome, and conduction disease. 5, 6 While variability in disease severity among mutationpositive individuals in this family is long recognized, 3 predictors of arrhythmia and SCD risk have remained elusive. By combining clinical observations in the family with experimental studies in Scn5a 1798insD/þ mice carrying the mouse homolog of the mutation, here, we uncovered a modulatory effect of hypertension and cardiac hypertrophy on disease severity and expression. In particular, the co-occurrence of cardiac hypertrophy was found to exacerbate cardiac conduction slowing and arrhythmia risk in the setting of the mutation, and was associated with a decreased efficacy of pacemaker treatment in preventing SCD. Our findings furthermore provide evidence for a potential therapeutic role of pharmacological late sodium current inhibition.
Methods
Details on study approval, SCN5A-1795insD mutation study population, clinical data collection, pathology reports, generation of Scn5a
and Scn5a 1798insD/þ -Nfatc2 -/-mice, transverse aortic constriction (TAC) and chow experiments, electrophysiological assessments in Langendorffperfused hearts, quantitative PCR assay and analysis and whole-mount in situ hybridization, and statistical analysis are provided in the Supplementary Methods. Data are presented as mean ± standard deviation or median (interquartile range), as appropriate.
Results
Hypertension and hypertrophy in older SCN5A-1795insD mutation-positive patients who died suddenly
Through an extensive genealogical search, we reconstructed the pedigree of the family with the SCN5A-1795insD mutation back to the 18th century, linking 164 mutation-positive individuals and 247 mutation-negative relatives ( Figure 1A) . Mutation-positive patients displayed (atrio-)ventricular conduction slowing, sinus node dysfunction, excessive ventricular repolarization abnormalities at slow heart rates, and SCD occurring predominantly at night. 3, 4 A total of 38 individuals died suddenly or suffered life-threatening ventricular arrhythmia (13 males, 25 females; average age at event 38 ± 18 years, range 13-76) ( Figure 1A and B). Twenty-five of these individuals were confirmed or obligate mutation-positive; genetic testing was not possible in the rest as these were deceased individuals from past generations, the majority of which died more than 50 years ago. Eighteen individuals who suffered SCD or a life-threatening arrhythmia were older than 40 years at the time of the event (4 males, 14 females, average age 54 ± 9 years, range 41-76) ( Figure 1A and B). Recent clinical information was available for 10 of these (all confirmed mutationpositive); nine of them had a clinical diagnosis of hypertension and/or evidence for the presence of left ventricular hypertrophy (LVH) on magnetic resonance imaging (MRI), echocardiography, or post-mortem examination (including increased heart weight; Table 1) , suggesting a modulatory effect of cardiac hypertrophy on arrhythmia risk. Post-mortem analysis furthermore indicated the additional presence of slight interstitial fibrosis (potentially hypertension-related) in three out of four patients ( Table 1) . Evidence for coronary artery disease, with hypertension as a major risk factor, was found in two patients. In one patient, small foci of subendocardial necrosis were found, but this was not associated with critically stenosing or thrombosed coronary lesions. The other patient displayed a fibrotic scar consistent with an old myocardial infarction without signs of recent-onset ischaemia.
Decreased pacemaker treatment efficacy in SCN5A-1795insD mutation-positive patients older than 40
Mutation-positive patients died suddenly predominantly during the night, and excessive QT-prolongation during (nocturnal) bradycardic episodes was frequently documented on Holter recordings. 3, 4, 7 Hence, a bradycardia-dependent trigger for arrhythmia was originally suspected, and pacemaker implantation has been routinely employed in the family to prevent SCD. 4 While this approach initially proved
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. Figure 1A) . All of them were older than 40 (age range 41-58 years), and in the majority, ventricular fibrillation, or tachycardia was documented (Table 1) , in addition to ventricular extrasystoles recorded during Holter monitoring or exercise testing in several cases. Figure 1D shows a pacemaker readout displaying a nocturnal, fast ventricular tachycardia (presumably polymorphic) in a 58-yearold female mutation-positive patient; following this episode, her pacemaker was replaced with an implantable cardioverter-defibrillator. These observations suggested an age-dependent shift towards a different arrhythmia triggering mechanism at older age with arrhythmias occurring despite prevention of bradycardia. Indeed, comparing the occurrence of SCD/life-threatening arrhythmia between individuals with and without pacemaker showed that while pacemaker implantation was highly protective in young mutation-positive patients, its efficacy in preventing arrhythmias and SCD was significantly decreased above the age of 40 years (P = 0.028; proportional hazard assumption of pacemaker implantation tested using the Schoenfeld residuals from a Cox regression model) ( Figure 1C) . Importantly, in six of the seven mutation-positive patients who suffered a life-threatening event despite pacemaker treatment, a history of hypertension was confirmed and/or the presence of LVH documented on MRI, echocardiography, or post-mortem examination ( Table 1) . These observations led us to hypothesize that the co-occurrence of the mutation with cardiac hypertrophy, developing with age secondary to for instance hypertension, plays a pivotal role in modulating arrhythmia risk.
The co-occurrence of cardiac hypertrophy is pro-arrhythmic in aged Scn5a 1798insD/þ mice
We further explored the modulatory role of cardiac hypertrophy in Scn5a 1798insD/þ mice carrying the exact mouse homolog of the human SCN5A-1795insD mutation. 5, 8 We have previously generated two distinct mouse lines harbouring the Scn5a 1798insD/þ mutation, with respectively the FVB/N and 129P2 inbred genetic background, enabling investigation of the effect of the mutation on different genetic backgrounds. In young adult mice, we previously demonstrated straindependent variable disease severity, with more pronounced conduction slowing and prolongation of repolarization in mutant mice of the 129P2 strain. 8 We now studied aged mice wild-type for the Scn5a gene (WT) and Scn5a 1798insD/þ mutant for the Scn5a gene (MUT) of both strains. The 129P2 strain was found to develop more cardiac hypertrophy with age as compared to the FVB/N strain. This feature was intrinsic to the 129P2 strain and independent of the mutation, since both aged WT-and MUT-129P2 mice displayed greater heart weight and higher expression levels of pro-hypertrophic markers as compared to aged WT-and MUT-FVB/N mice ( Figure 2A and B). These intrinsic strain-dependent differences in susceptibility to hypertrophy enabled a comparison of the pro-arrhythmic effect of the mutation in the presence (i. Table S1 ) and ex vivo (left ventricular activation time in isolated Langendorff-perfused hearts; Figure 2F and G). Moreover, 129P2-MUT mice exhibited significantly more spontaneous ventricular extrasystoles and arrhythmias in vivo ( Figure  2C and E) and an increased inducibility of ventricular arrhythmias ex vivo ( Figure 2H and I). While these observations do not provide a causal link, they are in line with a pro-arrhythmic interaction between hypertrophy and the mutation, similar to our observations in the SCN5A-1795insD family.
Chronic pressure overload elicits conduction delay and sudden death in Scn5a 1798insD/þ mice
To provide direct evidence for a modulatory effect of hypertrophy in the setting of the mutation, we subjected adult FVB/N-WT and FVB/ N-MUT mice (10-12 weeks old) to TAC (duration of 2 weeks), an intervention which leads to chronic pressure overload and consequent development of cardiac hypertrophy. Transverse aortic constriction induced similar extent of hypertrophy in WT and MUT mice, as illustrated by equal increases in heart mass and up-regulation of hypertrophic genes (Figure 3B and C; Supplementary material online, Table S2 ). However, approximately 35% of MUT-TAC mice died suddenly during the 2-week post-TAC period, while all WT-TAC and sham mice survived ( Figure 3A) . Continuous 24 h telemetric ECG recordings in a subset of MUT-TAC mice revealed progressive bradycardia and excessive (atrio-)ventricular conduction abnormalities prior to SCD (Supplementary material online, Figure S2 ). Electrocardiogram analysis in surviving MUT mice post-TAC uncovered a more pronounced increase in QRS-duration compared to WT (Supplementary material online, Table S3 ). Moreover, ex vivo measurements in isolated Langendorff-perfused hearts post-TAC showed atrioventricular delay and exacerbated ventricular conduction slowing in MUT but not WT mice (Figure 3D -G; Supplementary material online, Table S2 ). Hence, TAC elicited SCD and conduction Transverse aortic constriction-induced conduction abnormalities and SCD in Scn5a 1798insD/þ mice are attenuated by decreasing the hypertrophic response through genetic inhibition of the calcineurin-Nfat pathway Activation of the calcineurin-Nfat (Nuclear Factor of Activated T-cells) signaling pathway is known to play a major role in mediating the pro-hypertrophic consequences of chronic pressure overload of the heart. To investigate whether the more severe electrophysiological abnormalities in FVB/N-MUT mice post-TAC are the direct consequences of cardiac hypertrophy and not to other (indirect) effects of pressure overload, we abrogated the hypertrophic response by inducing genetic deletion of the main downstream effector of the calcineurin-Nfat pathway by crossing Scn5a 1798insD/þ mice with mice lacking Nfatc2 (Nfatc2 -/-). 9 ,10 WT and MUT (Scn5a 1798insD/þ ) mice deficient for Nfatc2 (Nfatc2 -/-), and littermate WT and MUT animals with unaltered Nfatc2 expression (Nfatc2 þ/þ ), were subjected to TAC for a period of 2 weeks. As expected, cardiac hypertrophy in response to pressure overload was attenuated in WT and MUT mice deficient for Nfatc2 (WT-Nfatc2 -/-and MUT-Nfatc2
-/-), as illustrated by lower heart weights and lower expression of hypertrophic genes when compared with WT-Nfatc2 þ/þ and MUT-Nfatc2 þ/þ ( Figure 4B and C, Supplementary material online, Table S4 ). No SCD was observed in MUT-Nfatc2 -/-mice subjected to TAC ( Figure 4A ), and the (atrio-)ventricular conduction abnormalities secondary to TAC Table S2 . Table S4 ). Hence, blocking the downstream, pro-hypertrophic signaling cascade prevented the TAC-induced conduction abnormalities and SCD in MUT mice, providing support for a direct interaction between the mutation and cardiac hypertrophy.
Chronic late sodium current inhibition prevents transverse aortic constrictioninduced conduction abnormalities and SCD in Scn5a 1798insD/þ mice
We have previously demonstrated that the SCN5A-1795insD mutation is associated with multiple biophysical defects including a gain of channel function due to sustained (late) inward sodium current. 5, 6 This mutation-induced enhanced late sodium current (I Na,late ) can be blocked through pharmacological inhibition. We, therefore, explored whether blocking this biophysical defect of the mutation would prevent the exacerbation of electrophysiological abnormalities associated with TAC in MUT mice. For this, we administered the I Na,late inhibitor Ranolazine by feeding WT and MUT mice either control or Ranolazine chow for the 2 weeks period of TAC or sham (starting 2 days after the TAC or sham procedure). Food intake and body weights were constant throughout the duration of the experiment and did not differ between groups (Supplementary material online, Figure S1 ). I Na,late inhibition decreased QTc-duration in sham mice, and moreover prevented TAC-induced QTc-prolongation (Supplementary material online, Table S3 ). Blocking I Na,late did not affect the magnitude of TAC-induced cardiac hypertrophy, as indicated by a similar increase in pro-hypertrophic markers in WT-TAC and MUT-TAC mice that were fed Ranolazine chow (Figure 4B and C; Supplementary material online, Table S2 ). Yet, I Na,late blockade prevented SCD and attenuated (atrio-)ventricular conduction abnormalities in MUT mice subjected to TAC ( Figure 4D -F, Supplementary material online, Table S2 ). Hence, pharmacological inhibition of the mutation-induced enhanced I Na,late rescued the TAC-induced deleterious interaction between hypertrophy and the Scn5a 1798insD/þ mutation.
Discussion
Our findings point to a modulatory effect of hypertension and consequent cardiac hypertrophy on age-dependent risk for sudden arrhythmic death and pacemaker treatment efficacy in the SCN5A-1795insD mutation-positive patients. This is supported by our observations in Scn5a 1798insD/þ mice carrying the homologous mutation, where cardiac hypertrophy (either occurring with age or induced by TAC) led to severe conduction disturbances and an increased risk for ventricular arrhythmias and/or SCD. This study for the first time provides evidence for a modulatory role of co-morbidity in modulating disease severity of an inherited arrhythmic disease, demonstrating a pro-arrhythmic gene-environment interaction.
Modulatory effect of cardiac hypertrophy on (age-dependent) arrhythmic phenotype
Cardiac hypertrophy, which commonly occurs as a consequence of hypertension, develops over time and progressively remodels the myocardium. Its impact is therefore expected to increase with age, potentially altering disease severity in mutation-positive patients in an age-dependent manner. The observed age-dependent shift from bradycardia-induced (prevented by pacemaker therapy) to apparent bradycardia-independent arrhythmias and SCD in older SCN5A-1795insD mutation-positive patients moreover indicates a modulatory effect on disease expression. Our clinical findings are further supported by our observations in Scn5a 1798insD/þ mice, where mice from the strain most prone to age-dependent hypertrophy (i.e. 129P2-Scn5a 1798insD/þ mice) developed a more pronounced arrhythmic phenotype with significantly more spontaneous and inducible ventricular arrhythmias. Although other factors besides hypertrophy, that differ between the patients and between the two mouse strains may also contribute, collectively this human and mouse data support the concept that age-dependent development of cardiac hypertrophy interacts with sodium channel dysfunction to predispose the heart to ventricular arrhythmias and SCD. Data obtained in the TAC studies in young-adult Scn5a 1798insD/þ mice provide direct proof of the modulatory role of hypertrophy on disease expression. Despite the fact that wild type and Scn5a 1798insD/þ mice developed similar extent of cardiac hypertrophy secondary to TAC, SCD and conduction abnormalities were observed only in Scn5a 1798insD/þ mice with chronic pressure overload. In contrast to aged 129P2-Scn5a 1798insD/þ mice however, no spontaneous or inducible ventricular arrhythmias were observed in mutant mice following TAC (data not shown). The young-adult age of the mice subjected to TAC, the relatively abrupt development of hypertrophy secondary to TAC (in contrast to gradual progression with age), and the short duration of TAC (two weeks) may underlie this apparent discrepancy. One should note however that as for aged Scn5a 1798insD/þ mice, young-adult Scn5a 1798insD/þ mice developed ventricular conduction slowing post-TAC, a phenomenon that is well established to promote ventricular arrhythmias.
Potential mechanisms underlying modulatory role of hypertrophy
The mechanisms underlying the modulatory, pro-arrhythmic effects of hypertension and consequent hypertrophy may be numerous and complex. Hypertrophy is associated with progressive electrical (alterations in sodium current and other ion channels), homeostatic (dysregulation of intracellular calcium homeostasis) and structural (collagen deposition) remodelling. [11] [12] [13] [14] These alterations may be further exacerbated in the setting of an SCN5A mutation, acting synergistically with the biophysical defects caused by the SCN5A mutation in creating a highly arrhythmogenic environment. 15, 16 In support of this, we found that similar levels of hypertrophy induced a pro-arrhythmic phenotype in Scn5a 1798insD/þ but not wild type mice, indicating a synergistic interaction between hypertrophy and the mutation. Moreover, TAC-induced conduction disturbances and SCD were prevented by either blocking the downstream pro-hypertrophic response (by genetic deletion of Nfatc2) or by pharmacological inhibition of the detrimental consequences of the mutation (i.e. through I Na,late inhibition). Enhanced I Na,late increases sodium influx, which may secondarily lead to increased intracellular calcium concentrations. The latter is a well-established pro-arrhythmic feature of hypertrophy and heart failure, and may be exacerbated in SCN5A-1795insD mutation-positive patients in the presence of hypertrophy. 17, 18 The involvement of the enhanced I Na,late defect in mediating, at least in part, the observed interaction with hypertrophy is supported by the fact that targeting this molecular defect by I Na,late blockade prevented SCD and attenuated (atrio-)ventricular conduction abnormalities in mutant mice post-TAC. While enhanced I Na,late is a well-established pro-arrhythmic consequence of hypertrophy, 18 one might speculate that other hypertension-associated pathways (including the renin angiotensin aldosterone system) may also be involved in mediating the role of hypertrophy in increasing arrhythmic propensity, with potential relevance for patient management.
Implications for age-dependent treatment efficacy
The observed age-dependent change in arrhythmia phenotype had crucial consequences for treatment efficacy in SCN5A-1795insD mutation-positive patients: while pacemaker implantation remained 100% efficacious in preventing SCD in young mutation-positive individuals, it no longer afforded complete protection over the age of 40. These findings therefore underline the necessity for additional treatment strategies in older SCN5A mutation-positive patients. Our combined observations in the family and in mice implicate a role for hypertension and consequent hypertrophy in disease expressivity with consequences for treatment efficacy, although other comorbidities may also play an as yet unidentified modulatory role. Our findings indicate a pro-arrhythmic interaction between hypertrophy and the mutation, and prevention of either hypertrophy (by genetic deletion of Nfatc2) or the effect of the mutation (by Ranolazine) was sufficient to prevent SCD in mutant mice subjected to TAC. Hence, clinical management of affected patients with either I Na,late inhibition or anti-hypertensive treatment (aimed at preventing LVH) is potentially beneficial, since either of these approaches would prevent the deleterious interaction between cardiac hypertrophy and the mutation. While I Na,late inhibition may have additional (long-term) benefits aside from restoration of repolarization, including the prevention of intracellular sodium/calcium dysregulation, it is as yet unclear whether this therapeutic approach will be clinically applicable in the near future. Ranolazine may have pro-arrhythmic side-effects due to its (limited) I Kr blocking properties, and the development of more selective I Na,late inhibitors (including Eleclazine) was discontinued. 19, 20 Thus, while awaiting (further) development of novel compounds targeting I Na,late , 20 current clinical management should focus on carefully monitoring SCN5A-1795insD mutation-positive patients for co-morbidities such as hypertension. In addition, hypertension should be aggressively treated early on to prevent LVH development, which should be regularly monitored by echocardiography. In particular, drugs targeting the renin-angiotensin system may be beneficial. 21 This approach is in line with the 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death, 22 which state that appropriate therapy should also take into account underlying diseases, co-morbidities, and associated medical conditions that may contribute to and/or exacerbate arrhythmia.
Limitations
While the homogeneity in genetic cause in the extended SCN5A-1795insD family allowed for detection of this interaction, it is associated with the limitation that transferability of these observations to other SCN5A mutations, although considered likely, will need to be explored. It is possible that our current findings are specific for 'overlap syndrome' mutations associated with both a loss and a gain of sodium channel function. Furthermore, while hypertension and/or hypertrophy was observed in the majority of older SCN5A-1795insD mutation-positive patients who suffered a life-threatening event despite pacemaker treatment, we currently do not know the exact prevalence of these co-morbidities in all mutation-positive and -negative individuals in the family.
Conclusion
Our findings show that a common co-morbidity (e.g. hypertension) may significantly affect arrhythmia risk and survival in inherited sodium channelopathy. The impact of such unrelated co-morbidities varies with age, leading to potential age-dependent changes in arrhythmia mechanism. As a consequence, efficacy of treatment strategies to prevent SCD in the setting of inherited arrhythmic disease may vary over time, underscoring the need for continuous diagnosis and monitoring of relevant co-morbidities and their rigorous treatment.
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